{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:44:52Z","timestamp":1794923092701,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jneuroim.2025.578613","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:50:54Z","timestamp":1744134654000},"page":"578613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01)"],"prefix":"10.1016","volume":"403","author":[{"given":"Panayiota","family":"Petrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Kassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarden","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Yaghmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehila","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Ginzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Karussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jneuroim.2025.578613_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fneur.2019.00280","article-title":"Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?","volume":"10","author":"Abdelhak","year":"2019","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578613_bb0015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578613_bb0020","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1177\/1352458510380089","article-title":"Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study","volume":"16","author":"Amato","year":"2010","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578613_bb0025","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/1352458511433303","article-title":"Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis","volume":"18","author":"Avsar","year":"2012","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578613_bb0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578613_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578613_bb0040","article-title":"Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation","volume":"5","author":"Baldassari","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578613_bb0050","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578613_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/13524585221137697","article-title":"Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients","volume":"29","author":"Barro","year":"2023","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578613_bb0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0065","first-page":"58","article-title":"Serum glial fibrillary acidic protein (GFAP) is a longitudinal indicator of disease progression in MS while neurofilament light chain (NfL) associates with therapy response in patients under B-cell depleting therapy","volume":"29","author":"Benkert","year":"2023","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578613_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000099158","article-title":"Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study","volume":"57","author":"Bergendal","year":"2007","journal-title":"Eur. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578613_bb0075","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578613_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/path.1650","article-title":"The cytoskeleton in neurodegenerative diseases","volume":"204","author":"Cairns","year":"2004","journal-title":"J. Pathol."},{"issue":"Pt 7","key":"10.1016\/j.jneuroim.2025.578613_bb0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/brain\/122.7.1341","article-title":"Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates","volume":"122","author":"Camp","year":"1999","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578613_bb0090","article-title":"Current status of Oral disease-modifying treatment effects on cognitive outcomes in multiple sclerosis: a scoping review","volume":"10","author":"Carlomagno","year":"2023","journal-title":"Bioengineering (Basel)."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578613_bb0095","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578613_bb0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578613_bb0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578613_bb0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578613_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458515604383","article-title":"No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy","volume":"22","author":"Damasceno","year":"2016","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578613_bb0120","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578613_bb0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578613_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.47588","article-title":"Serum Neurofilament light and multiple sclerosis progression independent of acute inflammation","volume":"5","author":"Gafson","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jneuroim.2025.578613_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578613_bb0140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","article-title":"Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world","volume":"81","author":"Goldman","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578613_bb0145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ene.13274","article-title":"Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis","volume":"24","author":"Hakansson","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578613_bb0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0155","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.neubiorev.2017.09.005","article-title":"Distinct cognitive impairments in different disease courses of multiple sclerosis-a systematic review and meta-analysis","volume":"83","author":"Johnen","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578613_bb0160","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578613_bb0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","author":"Karussis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578613_bb0170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"14","key":"10.1016\/j.jneuroim.2025.578613_bb0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.0b013e31821432ff","article-title":"Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis","volume":"76","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.jneuroim.2025.578613_bb0180","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.jneuroim.2025.578613_bb0185","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1177\/1352458519885613","article-title":"Neurofilament light levels are associated with long-term outcomes in multiple sclerosis","volume":"26","author":"Kuhle","year":"2020","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578613_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/13524585211032348","article-title":"Sustained reduction of serum neurofilament light chain over 7years by alemtuzumab in early relapsing\u2013remitting MS","volume":"28","author":"Kuhle","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"22","key":"10.1016\/j.jneuroim.2025.578613_bb0195","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009522","article-title":"Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"94","author":"Landmeyer","year":"2020","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578613_bb0200","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood Neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"issue":"Pt 4","key":"10.1016\/j.jneuroim.2025.578613_bb0205","first-page":"1089","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"299","key":"10.1016\/j.jneuroim.2025.578613_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2016.08.004","article-title":"Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis","author":"Ma\u00f1\u00e9-Mart\u00ednez","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578613_bb0215","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578613_bb0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578613_bb0225","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578613_bb0230","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578613_bb0235","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.jneuroim.2025.578613_bb0240","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578613_bb0245","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578613_bb0250","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14737175.2020.1760846","article-title":"Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring","volume":"20","author":"Preziosa","year":"2020","journal-title":"Expert. Rev. Neurother."},{"issue":"9899","key":"10.1016\/j.jneuroim.2025.578613_bb0255","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(13)61810-3","article-title":"Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases","volume":"382","author":"Rice","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578613_bb0260","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102810","article-title":"Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI","volume":"50","author":"Saraste","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578613_bb0270","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/brain\/awx154","article-title":"Cell-based therapeutic strategies for multiple sclerosis","volume":"140","author":"Scolding","year":"2017","journal-title":"Brain"},{"issue":"10130","key":"10.1016\/j.jneuroim.2025.578613_bb0275","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578613_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10072-015-2400-1","article-title":"Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review","volume":"37","author":"Vollmer","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578613_bb0285","article-title":"Neurofilaments in progressive multiple sclerosis: a systematic review","author":"Williams","year":"2020","journal-title":"J. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:51:58Z","timestamp":1746071518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"alternative-id":["S0165572825000943"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578613","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01)","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578613"}}